How much funding has Ancilia Biosciences raised?

Ancilia Biosciences has raised $5.2M in total funding, most recently a seed round.

When was Ancilia Biosciences founded?

Ancilia Biosciences was founded in 2019.

Where is Ancilia Biosciences headquartered?

Ancilia Biosciences is headquartered in Long Island City, New York, United States.

What industry is Ancilia Biosciences in?

Ancilia Biosciences operates in Biotech.

How many employees does Ancilia Biosciences have?

Ancilia Biosciences has 1-10 employees.

Ancilia Biosciences

CRISPR-mediated viral immunity. Designed by nature, harnessed by Ancilia.

Long Island City, United States · Founded 2019 · $5.2M raised

Biotech

Headquarters: Long Island City, New York
Employees: 1–10
Founded: 2019
Business Model: B2B

Website: anciliabio.com
Total Funding: $5.2M
Last Round: $5.2M SeedApr 2026
Rounds: 1

About

Ancilia Biosciences harnesses the natural function of CRISPR to create virus-resistant live bacterial products for human health and other applications. Its CoVE platform identifies viral bacteriophages and its EPIC platform engineers live biotherapeutics with immunity to those viruses. The company is advancing its first therapeutic candidate toward clinical trials for microbiome-related conditions.

Summary

Ancilia Biosciences is a Biotech company based in Long Island City, United States, founded in 2019. It has raised $5.2M in total across 1 round, most recently a $5.2M Seed round in Apr 2026.